Public Employees Retirement Association of Colorado reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 37.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 178,399 shares of the company’s stock after selling 105,644 shares during the period. Public Employees Retirement Association of Colorado owned 0.20% of Neurocrine Biosciences worth $13,842,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in Neurocrine Biosciences by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 6,922,294 shares of the company’s stock valued at $318,426,000 after buying an additional 186,329 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Neurocrine Biosciences by 2.6% during the 3rd quarter. Janus Henderson Group PLC now owns 5,507,763 shares of the company’s stock valued at $337,516,000 after buying an additional 140,639 shares in the last quarter. Perceptive Advisors LLC grew its holdings in Neurocrine Biosciences by 33.9% during the 3rd quarter. Perceptive Advisors LLC now owns 4,791,589 shares of the company’s stock valued at $293,629,000 after buying an additional 1,214,000 shares in the last quarter. State Street Corp grew its holdings in Neurocrine Biosciences by 5.1% during the 2nd quarter. State Street Corp now owns 2,710,196 shares of the company’s stock valued at $124,666,000 after buying an additional 131,141 shares in the last quarter. Finally, TimesSquare Capital Management LLC grew its holdings in Neurocrine Biosciences by 1.4% during the 3rd quarter. TimesSquare Capital Management LLC now owns 2,348,100 shares of the company’s stock valued at $143,892,000 after buying an additional 32,727 shares in the last quarter.
Neurocrine Biosciences, Inc. (NBIX) traded up $1.52 during trading hours on Wednesday, reaching $83.69. The company had a trading volume of 780,300 shares, compared to its average volume of 1,022,697. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences, Inc. has a one year low of $39.21 and a one year high of $91.82. The company has a market cap of $7,271.47, a P/E ratio of -39.37, a price-to-earnings-growth ratio of 6.41 and a beta of 0.26.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Tuesday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.11). The business had revenue of $94.52 million during the quarter, compared to analysts’ expectations of $94.00 million. During the same period in the prior year, the firm earned ($0.51) EPS. research analysts anticipate that Neurocrine Biosciences, Inc. will post -1.48 EPS for the current fiscal year.
A number of research firms have weighed in on NBIX. Oppenheimer set a $100.00 target price on Neurocrine Biosciences and gave the company a “buy” rating in a report on Wednesday. Barclays reaffirmed an “overweight” rating and set a $100.00 target price on shares of Neurocrine Biosciences in a report on Wednesday. JPMorgan Chase & Co. lifted their target price on Neurocrine Biosciences from $79.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday. BidaskClub raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Wednesday, January 31st. Finally, Leerink Swann reissued an “outperform” rating and set a $83.00 price objective (up previously from $72.00) on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. One investment analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $88.33.
In other Neurocrine Biosciences news, insider Haig P. Bozigian sold 1,625 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $79.12, for a total value of $128,570.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin Charles Gorman sold 3,750 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $78.89, for a total value of $295,837.50. The disclosure for this sale can be found here. Insiders sold 337,950 shares of company stock valued at $26,613,876 in the last quarter. Corporate insiders own 4.80% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/14/public-employees-retirement-association-of-colorado-has-13-84-million-stake-in-neurocrine-biosciences-inc-nbix.html.
Neurocrine Biosciences Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.